Join The Conversation Card Front 01 Copy

The Medtechy Daily: November 9

Posted on November 09, 2018 by Medtech[y] Staff

The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health.

Top Tweet


Patient Dies After Undertrained Surgeon Uses Intuitive Surgical's da Vinci for Mitral Valve SurgeryAccording to an article from the DailyMail, a patient died in 2015 from a relatively routine mitral valve surgery that was performed in conjunction with Intuitive Surgical's da Vinci robot.

Google to bring on Geisinger’s CEO to direct its healthcare efforts. Geisinger President and CEO David Feinberg plans to step down from the health system to take charge of the healthcare efforts at Google, according to reports. (FierceMedTech)

RTI Surgical Acquires Paradigm Spine. In early November, RTI Surgical ($RTIX) announced that they entered an agreement to acquire Paradigm Spine in a deal worth up to $300 million. (Medtechy)

NuVasive wins FDA nod for Cohere XLIF implant components. NuVasive (NSDQ:NUVA) said today it won FDA 510(k) clearance for Cohere porous PEEK implants that are part of its Extreme Lateral Interbody Fusion surgical spinal procedures. (MassDevice)

InspireMD Announces Third Quarter Earnings, Still On-Track to Submit CGuard EPS IDE in 2019. InspireMD ($NSPR) announced results for the third quarter, bringing in $769,000 in revenue compared to $718,000 during the same period in 2017. (Medtechy)

Drug prices on ads: as ‘relevant’ as percent daily value on food labels. President Trump announced late last month that his administration will push back on high drug costs through a number of proposals, including linking Medicare Part B prices to an international pricing index that includes 16 other countries and by requiring pharmaceutical companies to include drugs’ list prices in TV ads. (Stat)

Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial. Intact Vascular announced at the 15th annual VIVA conference in Las Vegas that its Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial successfully achieved both primary and secondary endpoints. (Medtechy)

Corindus Vascular Robotics Posts Positive Third Quarter Earnings. Corindus Vascular Robotics is up almost 12% in midday trading as the company released a positive third quarter earnings statement prior to the market open. (Medtechy)